SB414

3 stories · following the connections

Business

Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414

By Nasdaq OMXDec 5, 2017, 1:35 PM UTC

Business

Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide

By Nasdaq OMXOct 18, 2017, 11:05 AM UTC

Business

Novan Presents Preclinical Data from Inflammatory Skin Diseases Program

By Nasdaq OMXApr 27, 2017, 1:05 PM UTC